(CercleFinance.com) – The ophthalmology laboratory Nicox announces that the first of two phase 3 studies on its NCX 470 in glaucoma, the Mont Blanc study, has reached the efficacy required for approval in the United States, while being well tolerated.
The once-daily administered product indeed met its primary efficacy endpoint by demonstrating non-inferiority to latanoprost with an intraocular pressure (IOP) lowering effect of 8.0 to 9.7 mmHg compared to basic value.
It was statistically superior to baseline at four of the six endpoints, and numerically superior at all six points, but the secondary efficacy endpoint, statistical superiority to latanoprost, n was not reached.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
